-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TLC-6740 in Insulin Resistance
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TLC-6740 in Insulin Resistance report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TLC-6740 in Insulin Resistance Drug Details: TLC-6740 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPG-1860 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPG-1860 in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPG-1860 in Primary Biliary Cholangitis (Primary Biliary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LBP-8 in Primary Sclerosing Cholangitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LBP-8 in Primary Sclerosing Cholangitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LBP-8 in Primary Sclerosing Cholangitis Drug Details: LBP-8 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALG-009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ALG-009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ALG-009 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: ALG-055009...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LY-3885125 in Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LY-3885125 in Dyslipidemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-3885125 in Dyslipidemia Drug Details: LY-3885125 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ECC-5004 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ECC-5004 in Type 2 Diabetes report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ECC-5004 in Type 2 Diabetes Drug Details: ECC-5004 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Survodutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Survodutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Survodutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Survodutide...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Survodutide in Liver Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Survodutide in Liver Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Survodutide in Liver Fibrosis Drug Details: Survodutide (BI-456906) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TJC-0265 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TJC-0265 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TJC-0265 in Idiopathic Pulmonary Fibrosis Drug Details: TJC-0265 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ECC-4703 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ECC-4703 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ECC-4703 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: The...